Last reviewed · How we verify

Niacin deficiency — Treatment Landscape & Competitive Intelligence

Niacin deficiency (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Niacin deficiency, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Nicorette NICOTINE Sanofi Cholinergic Nicotinic Agonist [EPC] Neuronal acetylcholine receptor; alpha4/beta2 1991-01-01
Infuvite Adult Nicotinamide Pfizer Standardized Chemical Allergen [EPC] NAD-dependent protein deacetylase sirtuin-2 1953-01-01
Myoinositol Myoinositol University of Colorado, Denver

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 3 drugs in Niacin deficiency
  2. Pfizer · 1 drug in Niacin deficiency
  3. Sanofi · 1 drug in Niacin deficiency
  4. University of Colorado, Denver · 1 drug in Niacin deficiency

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Niacin deficiency:

Cite this brief

Drug Landscape (2026). Niacin deficiency — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/niacin-deficiency. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing